Histologic Evolution From Adenocarcinoma to Squamous Cell Carcinoma After Gefitinib Treatment Min-Shu Hsieh, MD, Jie-Yang Jhuang, MD, Syue-Fong Hua, Yueh-Hung Chou, MD The Annals of Thoracic Surgery Volume 99, Issue 1, Pages 316-319 (January 2015) DOI: 10.1016/j.athoracsur.2014.02.075 Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Case 1. (A) Chest computed tomography scan showing one huge lung tumor in the right lung. (B) The first biopsy showed an adenocarcinoma (hematoxylin and eosin stain, original magnification × 200) immunoreactive to thyroid transcription factor-1 (inset, original magnification × 200). (C) After tyrosine kinase inhibitor treatment, the residual tumor comprised only squamous cell carcinoma (hematoxylin and eosin stain, original magnification × 200), which was p40(+) (inset, original magnification × 200) and (D) strongly immunoreactive to anti-epidermal growth factor receptor E746–A750 del antibodies (original magnification × 400). The Annals of Thoracic Surgery 2015 99, 316-319DOI: (10.1016/j.athoracsur.2014.02.075) Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Case 2. (A) Chest computed tomography scan showing right lung tumor with massive pleural effusion. (B) The first biopsy showed an adenocarcinoma (hematoxylin and eosin stain, original magnification × 200) immunoreactive to thyroid transcription factor-1 (inset, original magnification × 400). (C) The second biopsy of the right pleural mass showed a squamous cell carcinoma (hematoxylin and eosin stain, original magnification × 200), which was p40(+) (inset, original magnification × 400) and (D) strongly immunoreactive to anti-epidermal growth factor receptor L858R antibodies (original magnification × 400). The Annals of Thoracic Surgery 2015 99, 316-319DOI: (10.1016/j.athoracsur.2014.02.075) Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions